FDA advisory committee rejects application for new drug for low sexual desire ...
New Drug Application, and medicine just called Flibanserin was filed by a large German pharmaceutical company Boehringer-Ingelheim. The company sells and other well-known drugs such as Micardis (high blood pressure), Flomax (enlarged prostate), and Zantac (indigestion).
FDA makes a final decision on the application, but such a decision is an advisory committee of reproductive health drugs influential, especially if it is unanimous. The committee consists of seven women and five men.
The Panel considered that efficacy was not great enough to justify the risks, which include side effects such as dizziness, nausea, and fatigue. One of the doctors, Kathleen Hoeger from the University of Rochester, called the research "incredibly important", but, as he told
Medicine has been proposed for treatment of low sexual desire, especially in Premenopausal Women. Although the slack periods of libido can occur at any time in human life, medicine is intended to be helpful in the treatment called "hypoactive sexual desire disorder" (hypoaktiivinen sexual desire disorder).This condition is described in the Diagnostic and Statistical Manual of Mental Disorders, the diagnostic manual of medical maladies that doctors.
